Praxis CEO says early efficacy data for PRAX-222 ‘especially exciting’

Praxis Precision Medicines provided an update on its clinical portfolio at the company’s R&D Day. In conjunction with the event, Marcio Souza, president and CEO of Praxis, stated: “We were thrilled to be able to share important updates from our portfolio. Especially exciting is the early efficacy data we have seen with our PRAX-222 program in SCN2A gain-of-function developmental epilepsies and encephalopathies. Additionally, we are well on our way to initiate our Essential3 program in essential tremor this quarter and have been very encouraged by the early response from the community about participating in these trials.” As of the cutoff date, EMBRAVE study data was evaluable for three of four dosing periods showing: Patients achieved a 44% median reduction in seizures versus baseline, on top of best available standard of care; Patients observed an increased number of days without seizures, achieving a median of 35% seizure free days over the dosing period compared to a baseline of 21% seizure free days; All patients achieved significant seizure reduction after one dose. Praxis said it intends to request a meeting in the fourth quarter of 2023 with the FDA to align on next steps for the PRAX-222 program.